Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 5/20 | 0.46 |
| ▸ | TYK2 | P29597 | 4/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899308 | 1.00 | PTGES (0.46) | PTGESTYK2IRAK4S100A4HPGD | |
| SCHEMBL9944733 | 0.88 | RAB9A (0.42) | PTGESTYK2S100A4HPGD | |
| SCHEMBL9899506 | 0.85 | PTGES (0.44) | PTGESTYK2IRAK4 | |
| SCHEMBL9899508 | 0.85 | PTGES (0.44) | PTGESTYK2IRAK4 | |
| SCHEMBL11970141 | 0.82 | HPGD (0.42) | PTGESS100A4HPGD | |
| SCHEMBL10170842 | 0.82 | HPGD (0.42) | PTGESS100A4HPGD | |
| SCHEMBL9946660 | 0.82 | PTGES (0.45) | PTGES | |
| SCHEMBL9946613 | 0.81 | PTGES (0.46) | PTGES | |
| SCHEMBL9946693 | 0.80 | PTGES (0.46) | PTGESIRAK4S100A4HPGD | |
| SCHEMBL9947033 | 0.80 | PTGES (0.46) | PTGESIRAK4S100A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076673-A1 | 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | PTGES 3/4885TYK2 4414/4885IRAK4 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.